Interactions: Decreases digoxin level. Increases drug action of barbituates, chloramphenicol half-life.
Toxicity if given with corticosteroids, phenytoin, or sulfamides.
Use cautiously with garlic, ginko, echinacea, ginseng, St. John's wort, Kava Kava, grape seed.
Suppresses positive reaction to uric acid, purified protein derivative, mumps, May cause false positive Candida pap smear.
Cancer of breast, cervix, colon, liver, ovary, pancreas, stomach, and rectum. Given in combination with levamisole after surgical resection in clients with Duke's stage C colon cancer.
MOA: prevention of thymidine symthetase production, thereby inhibiting DNA and RNA synthesis. Not phase specific.
Contra: Hypersensitivity, pregnancy, severe infection, myelo-suppression, marginal nutritional status. Reduce dose in clients with impaired hepatic or renal function or malnutrition.
SE: Stomatitis, N&V&D, alopecia, rash, photosensitivity, Diarrhea may be sever.
AR:bome marrow depression. Life threatening: thrombocytopenia, myelosuppression, hemorrhage, renal failure.
Interactions: bone marrow depressants increase chances of toxicity. Avoid live virus vaccines. May decrease albumin, increase excretion of 5-HIAA in urine. Use cautiously with genseng, St. John's Wort, gingko biloba. Topical pepermint oil and eucalyptus oil may increase absorption of topical 5-FU
MOA: affects cells in the M phase of the cell cycle and inhibits mitosis.
Contra: Fatal if given intrathecally. Don't give to patients receiving radiation therapy through ports into the liver. Hypersensitivity. Don't give to patients with charcot-Marie-Tooth syndrome.
Caution: Pregnancy, liver or kidney disease, neromuscular disease, infection.
SE: peripheral neuropathy, loss of deep tenon reflexes, phlebitis, constapation, cramps, nausea, vomiting, muscle weakness, reversible alopecia.
AR: sensory loss, hypotension, visual disterbances, ptosis, ileus, SIADH, hyponatremia, hyperuricemia, severe local reaction with extravasation, fever. Intestinal necrosis, seizures, coma, acute bronchospasm, bone marrow depression.
Interactions: Given 12-14 hrs prior to L-asparaginase to minimize toxixity. Increased risk of bronchospasams with mitomycin. decreases digoxin effects-monitor levels. mix only with normal saline or glucose in H2O - keep pH range at 3.5-5.5. May cause hyponatremia, hyperuricemia, anemia, leukopenia, thrombocytopenia.
ProcritTo treat anemia secondary to CRF or AZT treatment of HIV infections. Use in clients with anemia secondary to cancer chemotherapy.
MOA: increased production of RBCs triggered by hypoxia or anemia.
Contra: Unccontrolled hypertension, hypersensitivity to mamalian cell-derivedproducts or human albumin.
Caution: pregnancy, lactation, porphyia;safety in children not known; increased mortality and/or tumor progression, serious cardiovascular and thromboembolic events if target hemoglobin of 12g/dl exceeded.
SE: sense of well-being, hypertension, arthralgias, nausea, edema, fatigue, injection site reaction, rash, diarrhea, SOB
NeupogenTo decrease incidence of infection in clients receiving myelosuppressive chemotherapeutic agents, including clients with AML undergoing induction or consolidation therapy, and clients undergoing bone marrow transplant; adjunct to chemotherapy for both solid tumor and hematologic malignancies; and for mobilization of progenitor stem cells used in autologous transplant; also for treatment of clients with severe, chronic neutropenia.
MOA: increases production of neutrophils and enhances their phagocytosis.
Contra: hypersensitivity to Escherichia coli-derived proteins. 24 hrs before or after cytotoxic chemotherapy.
Caution: pregnancy, lactation, safety in children is not known.